US › Healthcare

Upstream Bio, Inc. (UPB)

US · Healthcare · Biotechnology

$6.79+5.76%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.0M
Revenue YoY
+82.7%
Net profit
$-40.6M
Profit YoY
-48.8%
EPS
$-0.75
EPS estimate
$-0.75
Net margin
-3,925.6%

EPS came in at -0.75 against a street estimate of -0.75 — a beat of 0.0%.

Key statistics

Market cap
$349.4M
Forward P/E
0.0
P/B
1.13
Book value
$5.59
EPS (TTM)
$-2.90
52-week high
$33.68
52-week low
$5.85
50-day MA
$7.06
200-day MA
$15.96

Analyst view

Analysts rate Upstream Bio, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $38.25.

Shareholding

Insiders
14.88%
Institutions
86.78%

Largest institutional holders

FundStake
FMR Inc14.89%
Orbimed Advisors, LLC10.46%
BlackRock Inc6.19%
Decheng Capital LLC5.01%
Enavate Sciences GP, LLC4.52%
Vanguard Capital Management, LLC3.44%
Federated Hermes Inc1.80%
Geode Capital Management, LLC1.75%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Upstream Bio, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.